EA200900572A1 - MICELLAR NANOPARTICLES WITH CHEMICAL SUBSTANCES - Google Patents

MICELLAR NANOPARTICLES WITH CHEMICAL SUBSTANCES

Info

Publication number
EA200900572A1
EA200900572A1 EA200900572A EA200900572A EA200900572A1 EA 200900572 A1 EA200900572 A1 EA 200900572A1 EA 200900572 A EA200900572 A EA 200900572A EA 200900572 A EA200900572 A EA 200900572A EA 200900572 A1 EA200900572 A1 EA 200900572A1
Authority
EA
Eurasian Patent Office
Prior art keywords
micelles
chemical substances
micellar nanoparticles
manufacture
solid composition
Prior art date
Application number
EA200900572A
Other languages
Russian (ru)
Other versions
EA026213B1 (en
Inventor
Ян П. Мешвитцер
Original Assignee
Солвей Фармасьютикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В. filed Critical Солвей Фармасьютикалс Б.В.
Publication of EA200900572A1 publication Critical patent/EA200900572A1/en
Publication of EA026213B1 publication Critical patent/EA026213B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Настоящее изобретение относится к термостабильной твердой композиции, содержащей нанометровые мицеллы, мицеллы содержат плохо растворимое химическое вещество, такое как биологически активное вещество, растворенное в материале вспомогательного вещества, и мицеллы включены в водорастворимый носитель. Изобретение дополнительно относится к способу изготовления термостабильной твердой композиции и к способу изготовления фармацевтических лекарственных форм, содержащих ее.The present invention relates to a thermostable solid composition containing nanometer micelles, the micelles contain a poorly soluble chemical such as an active agent, dissolved in the excipient material, and the micelles are included in a water-soluble carrier. The invention further relates to a method for the manufacture of a thermostable solid composition and to a method for the manufacture of pharmaceutical dosage forms containing it.

EA200900572A 2006-10-20 2007-10-19 Thermostable solid pharmaceutical composition comprising nanomicelles and process for preparing same EA026213B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85302306P 2006-10-20 2006-10-20
EP06122648 2006-10-20
PCT/EP2007/061194 WO2008046905A1 (en) 2006-10-20 2007-10-19 Micellar nanoparticles of chemical substances

Publications (2)

Publication Number Publication Date
EA200900572A1 true EA200900572A1 (en) 2009-10-30
EA026213B1 EA026213B1 (en) 2017-03-31

Family

ID=38661928

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900572A EA026213B1 (en) 2006-10-20 2007-10-19 Thermostable solid pharmaceutical composition comprising nanomicelles and process for preparing same

Country Status (9)

Country Link
EP (1) EP2083799A1 (en)
JP (1) JP5439182B2 (en)
KR (1) KR101434334B1 (en)
AU (1) AU2007312233B2 (en)
CA (1) CA2666587C (en)
EA (1) EA026213B1 (en)
IL (1) IL197701A (en)
NO (1) NO20091975L (en)
WO (1) WO2008046905A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071375A1 (en) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh FORMULATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF DEFICIENT PERMEABILITY, PREPARATION AND PRODUCT PROCESS
KR20110056516A (en) 2008-09-12 2011-05-30 크리티컬 파머수티컬스 리미티드 Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
AR075180A1 (en) * 2009-01-29 2011-03-16 Novartis Ag SOLID ORAL FORMULATIONS OF A PYRIDOID-PYRIMIDINONE
EP2841090A1 (en) * 2012-04-24 2015-03-04 Amylin Pharmaceuticals, LLC Site-specific enzymatic modification of exendins and analogs thereof
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
FR3014317B1 (en) * 2013-12-11 2016-04-22 Patrice Binay NOVEL PROCESS FOR THE PRODUCTION OF TRANSMUCAL PHARMACEUTICAL FORMULATIONS AND FORMATIONS THUS OBTAINED
EP3424493A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
WO2020107119A1 (en) * 2018-11-30 2020-06-04 Canopy Growth Corporation Compositions comprising a cannabinoid or a cannabis-derived compound, methods of making and use
EP4005561A4 (en) * 2019-07-25 2022-12-07 Beijing Shenogen Pharma Group Ltd. Nano-micelle preparation of icaritin and preparation method therefor and application thereof
CN112915121A (en) 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 Cannabinoid nano micelle preparation and preparation method thereof
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
AU2022315590A1 (en) * 2021-07-22 2024-01-18 Nicoventures Trading Limited Composition comprising a constituent, derivative or extract of cannabis
CA3225822A1 (en) * 2021-07-22 2023-01-26 Steven Alderman Compositions comprising constituents, derivatives or extracts of cannabis
WO2023002197A1 (en) * 2021-07-22 2023-01-26 Nicoventures Trading Limited Compositions comprising a constituent, derivative or extract of cannabis
IL309703A (en) * 2021-07-22 2024-02-01 Nicoventures Trading Ltd Constituent, derivative or extract of cannabis in a water soluble matrix

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
FR2804604B1 (en) * 2000-02-09 2005-05-27 Sanofi Synthelabo USE OF A CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF USEFUL DRUGS TO FACILITATE THE STOPPAGE OF TOBACCO CONSUMPTION
MXPA03009439A (en) * 2001-09-21 2004-02-12 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity.
CA2456606C (en) * 2001-09-21 2010-01-26 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
JP4994039B2 (en) * 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド Micellar system useful for delivery of lipophilic or hydrophobic compounds
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
KR20060123493A (en) * 2003-12-23 2006-12-01 알자 코포레이션 Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
CA2585175A1 (en) * 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
ES2545589T3 (en) * 2005-04-08 2015-09-14 Abbott Laboratories Oral pharmaceutical formulations comprising salts of fenofibric acid
JP2008536929A (en) * 2005-04-18 2008-09-11 ルビコン・リサーチ・ピーヴィーティー・エルティーディー Bio-enhancing composition

Also Published As

Publication number Publication date
IL197701A0 (en) 2009-12-24
CA2666587A1 (en) 2008-04-24
CA2666587C (en) 2015-12-22
JP5439182B2 (en) 2014-03-12
WO2008046905A1 (en) 2008-04-24
AU2007312233A1 (en) 2008-04-24
EA026213B1 (en) 2017-03-31
IL197701A (en) 2014-12-31
KR20090077074A (en) 2009-07-14
NO20091975L (en) 2009-07-09
KR101434334B1 (en) 2014-08-28
EP2083799A1 (en) 2009-08-05
AU2007312233B2 (en) 2012-09-20
JP2010506886A (en) 2010-03-04

Similar Documents

Publication Publication Date Title
EA200900572A1 (en) MICELLAR NANOPARTICLES WITH CHEMICAL SUBSTANCES
EA201071218A1 (en) IMPROVED COMPOSITIONS FOR ACTIVE PHARMACEUTICAL COMPONENTS WITH BAD PERMEABILITY
WO2008070538A3 (en) Micellar nanoparticles comprising botulinum toxin
EA200870219A1 (en) STABILIZED WITH VITAMIN E SUCCINAT PHARMACEUTICAL COMPOSITIONS, METHODS FOR THEIR PRODUCTION AND USE
EA200870559A1 (en) A STABLE PHARMACEUTICAL COMPOSITION CONTAINING A DOCETIX AND A METHOD OF MANUFACTURING THIS
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
CY1115825T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LEVETIRAKETAM AND THEIR PREPARATION PROCEDURE
GT200500045A (en) STABILIZED SUPERSATURED SOLIDS OF LIPOFILIC DRUGS
WO2010047765A8 (en) Nanostructures for drug delivery
MX2011006771A (en) Preparation method of polymeric micelles composition containing a poorly water-soluble drug.
ZA200803350B (en) Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
TW200640502A (en) Tablets with improved drug substance dispersibility
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
WO2008017867A3 (en) Antiretroviral solid oral composition with at least one water insoluble polymer
CL2009001080A1 (en) Process for encapsulating biologically active agents in a particulate carrier, comprising solubilizing in a hydrophobic ion pairing agent and a solvent, dissolving, emulsifying, and obtaining the carrier; vehicle in the form of particles; and pharmaceutical composition comprising the vehicle.
TR200806298A2 (en) Pharmaceutical formulation
AR073056A1 (en) IMPROVEMENTS RELATED TO NANODISPERSE COMPOSITIONS.
ATE438385T1 (en) PHARMACEUTICAL COMPOSITION
HK1120417A1 (en) Stable nanoparticle formulations
UA97496C2 (en) Composition of embedded micellar nanoparticles and process for preparing thereof
AR064104A1 (en) DOSAGE FORMS IN VALSARTAN MICROEMULSION, AND METHODS TO PREPARE THEM
WO2010079052A3 (en) Nanoparticle compositions
CY1109541T1 (en) PHARMACEUTICAL FORMULATION FOR OSTEOHTHRITIS THERAPY CONTAINING CLODRONIC ACID AND HALURONIC ACID
UY30126A1 (en) A NEW PHARMACEUTICALLY ACCEPTABLE SALT OF 2-HIDROXI-3- (5- (MORFOLIN-4-ILMETIL) -PIRIDIN-2-L) 1H-INDOL-5-CARBONITRILE, PROCEDURES FOR THE PREPARATION, COMPOSITIONS CONTAINING IT AND APPLICATIONS
TR200909785A1 (en) Pharmaceutical compositions containing cefdinir as the active agent.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU